Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedrine Alkaloid Products Linked To AERs In 78% Of Cases - CDER

This article was originally published in The Tan Sheet

Executive Summary

The number of ephedrine alkaloid-containing dietary supplements available for sale in the U.S. has more than tripled during the last five years, a Center for Food Safety & Applied Nutrition survey finds.
Advertisement

Related Content

Ephedrine Alkaloid AERs Nearly Double Over Two Years - AAPCC Data
Ephedrine Alkaloid AERs Nearly Double Over Two Years - AAPCC Data
Ephedrine Alkaloid AERs Nearly Double Over Two Years - AAPCC Data
Ephedrine Alkaloid Serious AEs Consistent With Background Levels - Industry
Ephedrine Alkaloid Serious AEs Consistent With Background Levels - Industry
Ephedrine Alkaloid Serious AEs Consistent With Background Levels - Industry
Ephedrine Alkaloid/Caffeine Combos Risk Unproven - Metabolife
Ephedrine alkaloids
Texas Ephedrine 18 AERs Too Few To Support MedWatch Proposal - AHPA
Individual Susceptibility To Ephedrine Alkaloid AEs Cited By FDA Consultants

Topics

Advertisement
UsernamePublicRestriction

Register

PS091060

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel